Concepts (127)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Cryoglobulinemia | 2 | 2018 | 144 | 0.31 | Why? |
| Polypharmacology | 1 | 2021 | 33 | 0.23 | Why? |
| Drug Interactions | 4 | 2021 | 1653 | 0.22 | Why? |
| Enterococcus | 1 | 2021 | 73 | 0.21 | Why? |
| Sex Ratio | 1 | 2021 | 69 | 0.21 | Why? |
| Multiple Chronic Conditions | 1 | 2021 | 115 | 0.21 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 2 | 2021 | 1261 | 0.20 | Why? |
| Proteinuria | 1 | 2020 | 474 | 0.16 | Why? |
| Gram-Positive Bacterial Infections | 1 | 2021 | 323 | 0.16 | Why? |
| Serum Albumin | 1 | 2020 | 571 | 0.16 | Why? |
| Risk Adjustment | 1 | 2021 | 730 | 0.16 | Why? |
| Systemic Vasculitis | 1 | 2017 | 74 | 0.16 | Why? |
| Blood Component Removal | 1 | 2018 | 175 | 0.15 | Why? |
| Chagas Disease | 1 | 2018 | 155 | 0.15 | Why? |
| Compassionate Use Trials | 1 | 2020 | 632 | 0.15 | Why? |
| Drug Prescriptions | 2 | 2021 | 1062 | 0.14 | Why? |
| Anti-HIV Agents | 2 | 2018 | 2209 | 0.14 | Why? |
| Italy | 14 | 2021 | 38444 | 0.12 | Why? |
| Emigrants and Immigrants | 2 | 2018 | 888 | 0.12 | Why? |
| Receptors, Interleukin-6 | 1 | 2020 | 1383 | 0.12 | Why? |
| Plasma Exchange | 1 | 2018 | 763 | 0.11 | Why? |
| Communicable Diseases, Imported | 1 | 2018 | 843 | 0.10 | Why? |
| Anti-Retroviral Agents | 1 | 2018 | 1099 | 0.10 | Why? |
| Lopinavir | 2 | 2020 | 4308 | 0.09 | Why? |
| HIV Infections | 3 | 2020 | 11620 | 0.09 | Why? |
| Adenosine Monophosphate | 3 | 2021 | 5652 | 0.09 | Why? |
| Alanine | 3 | 2021 | 5687 | 0.09 | Why? |
| Ritonavir | 2 | 2020 | 4212 | 0.09 | Why? |
| Malaria | 1 | 2018 | 1097 | 0.09 | Why? |
| Pharmaceutical Preparations | 1 | 2021 | 1897 | 0.08 | Why? |
| Ambulatory Care Facilities | 1 | 2017 | 2063 | 0.07 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.07 | Why? |
| Transients and Migrants | 1 | 2017 | 1468 | 0.07 | Why? |
| Influenza Vaccines | 1 | 2020 | 2941 | 0.07 | Why? |
| Referral and Consultation | 1 | 2020 | 4816 | 0.07 | Why? |
| Adrenal Cortex Hormones | 1 | 2021 | 6537 | 0.07 | Why? |
| Hospitalization | 5 | 2021 | 54280 | 0.06 | Why? |
| Sepsis | 1 | 2021 | 3517 | 0.06 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.06 | Why? |
| Pharmacokinetics | 1 | 2021 | 41 | 0.06 | Why? |
| Potentially Inappropriate Medication List | 1 | 2021 | 55 | 0.05 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.05 | Why? |
| Pneumonia | 1 | 2020 | 5652 | 0.05 | Why? |
| Critical Illness | 2 | 2021 | 17281 | 0.05 | Why? |
| Retrospective Studies | 9 | 2021 | 105322 | 0.05 | Why? |
| Hydroxychloroquine | 2 | 2020 | 12447 | 0.05 | Why? |
| Transaminases | 1 | 2020 | 152 | 0.05 | Why? |
| Male | 17 | 2021 | 367725 | 0.05 | Why? |
| Intensive Care Units | 3 | 2021 | 29594 | 0.05 | Why? |
| Female | 17 | 2021 | 380317 | 0.05 | Why? |
| Prescriptions | 1 | 2020 | 258 | 0.05 | Why? |
| Middle Aged | 14 | 2021 | 270681 | 0.05 | Why? |
| El Salvador | 1 | 2018 | 27 | 0.05 | Why? |
| Respiratory Insufficiency | 1 | 2020 | 7301 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.04 | Why? |
| Drug Tolerance | 1 | 2018 | 100 | 0.04 | Why? |
| Nitroimidazoles | 1 | 2018 | 69 | 0.04 | Why? |
| Bolivia | 1 | 2018 | 187 | 0.04 | Why? |
| Aged | 11 | 2021 | 215776 | 0.04 | Why? |
| Antipyretics | 1 | 2018 | 107 | 0.04 | Why? |
| Lost to Follow-Up | 1 | 2017 | 79 | 0.04 | Why? |
| Polypharmacy | 1 | 2020 | 347 | 0.04 | Why? |
| Humans | 24 | 2021 | 930598 | 0.04 | Why? |
| Cryoglobulins | 1 | 2017 | 51 | 0.04 | Why? |
| Trypanosoma cruzi | 1 | 2018 | 133 | 0.04 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2018 | 309 | 0.04 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.04 | Why? |
| Risk Factors | 6 | 2020 | 71621 | 0.04 | Why? |
| Antiviral Agents | 4 | 2020 | 41703 | 0.04 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.04 | Why? |
| Calcium Channel Blockers | 1 | 2018 | 367 | 0.04 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.03 | Why? |
| Age Factors | 3 | 2021 | 21039 | 0.03 | Why? |
| Comorbidity | 1 | 2018 | 34796 | 0.03 | Why? |
| Complement System Proteins | 1 | 2017 | 380 | 0.03 | Why? |
| Health Services Accessibility | 1 | 2017 | 10697 | 0.03 | Why? |
| Logistic Models | 2 | 2018 | 9089 | 0.03 | Why? |
| Data Accuracy | 1 | 2018 | 715 | 0.03 | Why? |
| Sex Factors | 2 | 2021 | 11014 | 0.03 | Why? |
| Latin America | 1 | 2018 | 1721 | 0.03 | Why? |
| CD4 Lymphocyte Count | 1 | 2017 | 1517 | 0.03 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.03 | Why? |
| Vaccination Coverage | 1 | 2020 | 1249 | 0.03 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| Treatment Outcome | 3 | 2021 | 51732 | 0.02 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.02 | Why? |
| Taste Disorders | 1 | 2020 | 1720 | 0.02 | Why? |
| Pandemics | 6 | 2020 | 389249 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2020 | 4758 | 0.02 | Why? |
| Self Report | 1 | 2020 | 3802 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Adult | 6 | 2021 | 244371 | 0.02 | Why? |
| RNA, Messenger | 1 | 2021 | 5131 | 0.02 | Why? |
| Cross-Sectional Studies | 3 | 2020 | 53120 | 0.02 | Why? |
| Antimalarials | 1 | 2018 | 2505 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Inflammation Mediators | 1 | 2017 | 2654 | 0.02 | Why? |
| Aged, 80 and over | 3 | 2021 | 88759 | 0.02 | Why? |
| Prevalence | 2 | 2018 | 25773 | 0.02 | Why? |
| Prognosis | 2 | 2020 | 32490 | 0.02 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
| Patient Discharge | 1 | 2021 | 5696 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.02 | Why? |
| Fever | 1 | 2020 | 7795 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 7868 | 0.01 | Why? |
| Immunoassay | 1 | 2018 | 4485 | 0.01 | Why? |
| Acute Kidney Injury | 1 | 2020 | 5762 | 0.01 | Why? |
| Travel | 1 | 2018 | 7220 | 0.01 | Why? |
| Health Status Disparities | 1 | 2017 | 4072 | 0.01 | Why? |
| Adolescent | 2 | 2020 | 86841 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2020 | 10083 | 0.01 | Why? |
| Disease Progression | 1 | 2017 | 13580 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.01 | Why? |
| Vaccination | 1 | 2020 | 19050 | 0.01 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.01 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.01 | Why? |
| Biomarkers | 1 | 2017 | 23361 | 0.01 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.01 | Why? |
| Young Adult | 1 | 2020 | 93724 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2017 | 48226 | 0.01 | Why? |
| Child | 1 | 2018 | 70012 | 0.01 | Why? |
Oreni's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(127)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(98)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_